Cargando…

STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma

Objective: Photodynamic therapy (PDT) using Talaporfin Sodium (TS) is a novel therapeutic strategy to improve local tumor control in high-grade glioma. TS is a photosensitizer that accumulates in tumor cells and produces highly toxic free radicals by intraoperative irradiation of laser with a 664nm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohno, Makoto, Kawauchi, Daisuke, Hayashi, Yoshiharu, Satomi, Kaishi, Miyakita, Yasuji, Takahashi, Masamichi, Yanagisawa, Shunsuke, Tamura, Yukie, Kikuchi, Miyu, Hamada, Akinobu, Narita, Yoshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664632/
http://dx.doi.org/10.1093/noajnl/vdab159.051
_version_ 1784613882428391424
author Ohno, Makoto
Kawauchi, Daisuke
Hayashi, Yoshiharu
Satomi, Kaishi
Miyakita, Yasuji
Takahashi, Masamichi
Yanagisawa, Shunsuke
Tamura, Yukie
Kikuchi, Miyu
Hamada, Akinobu
Narita, Yoshitaka
author_facet Ohno, Makoto
Kawauchi, Daisuke
Hayashi, Yoshiharu
Satomi, Kaishi
Miyakita, Yasuji
Takahashi, Masamichi
Yanagisawa, Shunsuke
Tamura, Yukie
Kikuchi, Miyu
Hamada, Akinobu
Narita, Yoshitaka
author_sort Ohno, Makoto
collection PubMed
description Objective: Photodynamic therapy (PDT) using Talaporfin Sodium (TS) is a novel therapeutic strategy to improve local tumor control in high-grade glioma. TS is a photosensitizer that accumulates in tumor cells and produces highly toxic free radicals by intraoperative irradiation of laser with a 664nm wavelength. However, little is known about the treatment outcomes of PDT in recurrent high-grade gliomas (rHGG). In this study, we investigated the treatment outcome of PDT in rHGG and evaluated the correlation between intratumoral TS accumulation and outcomes. Methods: We included 21 patients with rHGG and 22 tumors, who were treated by PDT between June 2016 and March 2021. TS was transvenously administered 22–26 hours before PDT. Intratumoral TS concentrations were measured by liquid chromatography using frozen tissue. Results: The rHGGs included 10 glioblastoma, IDH1/2-wildtype (GBM, IDH1/2-WT: 45.5%), 3 GBM, IDH1/2-mutant (GBM, IDH1/2-Mut: 13.6%), 7 anaplastic oligodendroglioma, IDH1/2-Mut/codel (AO, IDH1/2-Mut/codel: 31.8%), 1 anaplastic astrocytoma, IDH1/2-WT (AA, IDH1/2-WT: 4.5%), 1 high-grade astrocytoma, IDH1/2-WT (4.5%). The median local progression free survival (PFS) time after PDT was 3.6 months and the median survival time from PDT was 19.4 months. The intratumoral TS concentrations of 7 tumors (TS(-): 31.8%) were below the limit of quantification, and the intratumoral TS concentrations of the remaining 15 tumors (TS(+)) were 43.5 ng/mg-protein (14.7–132 ng/mg-protein). The intratumoral TS concentrations were not significantly associated with IDH1/2 mutation status, cellularity, tumor grade, and pattern of enhancement. The median PFS from PDT tended to be longer in TS(+) than in TS(-) (TS(+): 6.3 vs TS(-): 1.4 months, p = 0.054). Conclusions: We found that the intratumoral TS concentrations were heterogeneous and 31.8% were below the limit of quantification. TS(+) tended to have better local tumor control than TS(-), suggesting the intratumoral TS accumulation have an impact of treatment outcomes of PDT.
format Online
Article
Text
id pubmed-8664632
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86646322021-12-13 STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma Ohno, Makoto Kawauchi, Daisuke Hayashi, Yoshiharu Satomi, Kaishi Miyakita, Yasuji Takahashi, Masamichi Yanagisawa, Shunsuke Tamura, Yukie Kikuchi, Miyu Hamada, Akinobu Narita, Yoshitaka Neurooncol Adv Supplement Abstracts Objective: Photodynamic therapy (PDT) using Talaporfin Sodium (TS) is a novel therapeutic strategy to improve local tumor control in high-grade glioma. TS is a photosensitizer that accumulates in tumor cells and produces highly toxic free radicals by intraoperative irradiation of laser with a 664nm wavelength. However, little is known about the treatment outcomes of PDT in recurrent high-grade gliomas (rHGG). In this study, we investigated the treatment outcome of PDT in rHGG and evaluated the correlation between intratumoral TS accumulation and outcomes. Methods: We included 21 patients with rHGG and 22 tumors, who were treated by PDT between June 2016 and March 2021. TS was transvenously administered 22–26 hours before PDT. Intratumoral TS concentrations were measured by liquid chromatography using frozen tissue. Results: The rHGGs included 10 glioblastoma, IDH1/2-wildtype (GBM, IDH1/2-WT: 45.5%), 3 GBM, IDH1/2-mutant (GBM, IDH1/2-Mut: 13.6%), 7 anaplastic oligodendroglioma, IDH1/2-Mut/codel (AO, IDH1/2-Mut/codel: 31.8%), 1 anaplastic astrocytoma, IDH1/2-WT (AA, IDH1/2-WT: 4.5%), 1 high-grade astrocytoma, IDH1/2-WT (4.5%). The median local progression free survival (PFS) time after PDT was 3.6 months and the median survival time from PDT was 19.4 months. The intratumoral TS concentrations of 7 tumors (TS(-): 31.8%) were below the limit of quantification, and the intratumoral TS concentrations of the remaining 15 tumors (TS(+)) were 43.5 ng/mg-protein (14.7–132 ng/mg-protein). The intratumoral TS concentrations were not significantly associated with IDH1/2 mutation status, cellularity, tumor grade, and pattern of enhancement. The median PFS from PDT tended to be longer in TS(+) than in TS(-) (TS(+): 6.3 vs TS(-): 1.4 months, p = 0.054). Conclusions: We found that the intratumoral TS concentrations were heterogeneous and 31.8% were below the limit of quantification. TS(+) tended to have better local tumor control than TS(-), suggesting the intratumoral TS accumulation have an impact of treatment outcomes of PDT. Oxford University Press 2021-12-06 /pmc/articles/PMC8664632/ http://dx.doi.org/10.1093/noajnl/vdab159.051 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Ohno, Makoto
Kawauchi, Daisuke
Hayashi, Yoshiharu
Satomi, Kaishi
Miyakita, Yasuji
Takahashi, Masamichi
Yanagisawa, Shunsuke
Tamura, Yukie
Kikuchi, Miyu
Hamada, Akinobu
Narita, Yoshitaka
STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
title STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
title_full STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
title_fullStr STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
title_full_unstemmed STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
title_short STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
title_sort stmo-17 treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664632/
http://dx.doi.org/10.1093/noajnl/vdab159.051
work_keys_str_mv AT ohnomakoto stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT kawauchidaisuke stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT hayashiyoshiharu stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT satomikaishi stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT miyakitayasuji stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT takahashimasamichi stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT yanagisawashunsuke stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT tamurayukie stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT kikuchimiyu stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT hamadaakinobu stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma
AT naritayoshitaka stmo17treatmentoutcomeofphotodynamictherapyusingtalaporfinsodiumforrecurrenthighgradeglioma